In the months ahead, we're keeping a close eye on several phase 3 readouts, especially from MNOV and CMPX. These trials pose both opportunities and risks for investors, with the potential to reshape markets for various conditions, including Amyotrophic Lateral Sclerosis and Biliary Tract Cancer. We’ll dissect the clinical trial results expected in late 2026 and early 2027 to offer insights into their implications for stakeholders.
Upcoming Phase 3 Readouts: Key Insights and Expectations
The full Phase 2 and Phase 3 readouts to watch
| Date | Ticker | Drug | Indication | Phase | PoA |
|---|---|---|---|---|---|
| 2027-04 | MNOV | MN-166, placebo (+0% run-up) | Amyotrophic Lateral Sclerosis | PHASE2 | n/a |
| 2026-12-31 | MNOV | MN-001, MN-001 placebo (+0% run-up) | Diabetes Mellitus, Type 2 | PHASE2 | n/a |
| 2026-12-01 | CMPX | CTX-009, Paclitaxel (+18.3% run-up) | Biliary Tract Cancer | PHASE2 | n/a |
| 2026-09-28 | MLTX | Sonelokimab | Hidradenitis Suppurativa | PHASE3 | n/a 🔒 |
| 2027-02-04 | MLTX | Sonelokimab, Placebo | Arthritis, Psoriatic | PHASE3 | n/a 🔒 |
| 2027-09-30 | ALT | Pemvidutide, Placebo | Alcohol-associated Liver Disease | PHASE2 | n/a 🔒 |
| 2026-11 | DBVT | DBV712 250 mcg, Placebo | Allergy | PHASE3 | n/a 🔒 |
| 2029-05 | MIRM | Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mg | Chronic Hepatitis D Infection | PHASE2 | n/a 🔒 |
| 2026-10 | MIRM | Maralixibat, Placebo | Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | PHASE3 | n/a 🔒 |
| 2030-01 | CYTK | Aficamten, Placebo | Pediatric | PHASE2 | n/a 🔒 |
| 2026-09-30 | GSK | GSK4527226, Placebo | Alzheimer's Disease | PHASE2 | n/a 🔒 |
MNOV's MN-166: The Phase 2 Readout for ALS
MNOV is preparing for a crucial phase 2 readout of MN-166 in Amyotrophic Lateral Sclerosis, set for April 2027. This trial could be significant, given ALS's devastating impact and the unmet needs it presents. MN-166 aims to modify the disease's progression, a challenging feat in clinical trials. Despite this, the market has shown no major movement ahead of the readout, with a 0% run-up, suggesting either cautious optimism or a lack of awareness about the potential impact. Without placebo-controlled data available, MNOV faces pressure to produce compelling results that could justify moving to phase 3 trials.
MNOV's MN-001: A Phase 2 Readout for Type 2 Diabetes
MNOV also has a phase 2 readout for MN-001, targeting Type 2 Diabetes, scheduled for December 31, 2026. With diabetes affecting millions globally, positive results could tap into a substantial market. The drug works by enhancing insulin sensitivity, crucial for managing blood glucose levels. Similar to MN-166, the trial has seen a 0% run-up, indicating that investors haven't yet anticipated the potential upside of successful results. This could be a buying opportunity if the data turns out favorable.
CMPX's CTX-009: Anticipating Phase 2 Readout for Biliary Tract Cancer
CMPX is gearing up to release its phase 2 readout for CTX-009, a new treatment for Biliary Tract Cancer, on December 1, 2026. This challenging indication, with few treatment options, means a successful trial could have a big impact. The drug is being tested against Paclitaxel, a well-known chemotherapy agent, and preliminary data suggests promising efficacy. With an 18.3% run-up, investors clearly expect positive outcomes, showing interest and confidence in CMPX's approach. A statistically significant improvement over Paclitaxel could significantly revalue CMPX's stock.
Upcoming Clinical Trial Results: A Broader Look
Beyond these immediate phase 2 readouts, other trials on the horizon deserve attention. MLTX's Sonelokimab for Hidradenitis Suppurativa is due for a readout on September 28, 2026. This disease has drawn interest due to its chronic nature and demand for effective treatments. Similarly, GSK's GSK4527226 for Alzheimer's Disease is scheduled for a readout on September 30, 2026. These trials could introduce new therapeutic options in often underserved fields.
Market Dynamics and Investor Sentiment
Current market sentiment shows cautious optimism as investors consider the potential of these upcoming phase 2 readouts. The lack of significant stock price increases for some candidates suggests the market might not fully grasp the implications of positive trial results. This scenario could be a chance for keen investors to analyze data and market conditions closely. Approaching these readouts, expect increased volatility, especially for stocks like MNOV and CMPX in high-stakes areas.
The Importance of Monitoring Insider Activity
Insider activity often offers valuable insights into management's confidence regarding upcoming phase 3 readouts. We assess each one on approval probability, insider activity, and options positioning. Monitoring these indicators can help investors gauge sentiment and potential movements before key data releases. For instance, increased insider buying ahead of significant trial results may signal confidence in positive outcomes. On the other hand, selling could be a warning sign.
The bottom line
Staying informed and engaged with the data as these critical phase 2 readouts approach will be vital for making astute investment decisions.
Frequently asked questions
What is a phase 3 readout?
A phase 3 readout refers to the results from a late-stage clinical trial that assesses the effectiveness and safety of a treatment in a larger patient population.
When are the next significant phase 2 readouts expected?
The next significant phase 2 readouts are expected from MNOV on December 31, 2026, and CMPX on December 1, 2026.
What should investors look for before a phase 3 readout?
Investors should monitor insider trading activity, market sentiment, and any preliminary data that may indicate the potential success of the upcoming trial.
Why is monitoring run-up percentages important?
Monitoring run-up percentages helps investors gauge market expectations and sentiment regarding the potential success of upcoming clinical trial results.